BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33438540)

  • 1. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
    Parmar K; Shah J
    Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
    Parmar K; Oza K
    AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
    Patel PJ; Gajera BY; Dave RH
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA; ElMeshad AN; Fares AR
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
    Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
    Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation.
    Chang D; Ma Y; Cao G; Wang J; Zhang X; Feng J; Wang W
    Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1018-1024. PubMed ID: 28749189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabrication of Ibrutinib Nanosuspension by Quality by Design  Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
    Rangaraj N; Pailla SR; Chowta P; Sampathi S
    AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
    Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution.
    Rashed M; Dadashzadeh S; Bolourchian N
    Iran J Pharm Res; 2022 Dec; 21(1):e129409. PubMed ID: 36942076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
    Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
    Pınar SG; Canpınar H; Tan Ç; Çelebi N
    Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
    Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surface Engineering of Fenofibrate Nanocrystals Using Nano-by-Design Multivariate Integration: A Biopharmaceutical and Pharmacokinetic Perspective.
    Gite S; Kakade P; Patravale V
    Curr Drug Deliv; 2021; 18(9):1314-1329. PubMed ID: 33655832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR; Bari SB
    Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability.
    Rahim H; Sadiq A; Ullah R; Bari A; Amin F; Farooq U; Ullah Jan N; Mahmood HM
    Int J Nanomedicine; 2020; 15():8999-9009. PubMed ID: 33235448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
    Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
    Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.